Harrow Health (HROW) Scheduled to Post Earnings on Thursday

Harrow Health (NASDAQ:HROWGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Harrow Health (NASDAQ:HROWGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.09). Harrow Health had a positive return on equity of 4.36% and a negative net margin of 24.84%. The company had revenue of $20.19 million during the quarter, compared to the consensus estimate of $21.35 million. During the same period in the prior year, the firm earned $0.07 earnings per share. On average, analysts expect Harrow Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of HROW opened at $6.48 on Thursday. The company has a quick ratio of 5.81, a current ratio of 6.24 and a debt-to-equity ratio of 6.56. The business’s 50 day moving average price is $7.18 and its 200-day moving average price is $8.51. Harrow Health has a 52 week low of $6.27 and a 52 week high of $12.99. The stock has a market cap of $175.15 million, a P/E ratio of -9.53 and a beta of 0.96.

Separately, Zacks Investment Research cut Harrow Health from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 15th.

In other news, major shareholder Opaleye Management Inc. acquired 28,557 shares of the firm’s stock in a transaction that occurred on Tuesday, April 12th. The stock was bought at an average cost of $6.75 per share, for a total transaction of $192,759.75. Following the acquisition, the insider now directly owns 3,165,000 shares in the company, valued at $21,363,750. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 12.43% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its holdings in Harrow Health by 466.4% in the 4th quarter. Bank of America Corp DE now owns 4,463 shares of the company’s stock worth $39,000 after acquiring an additional 3,675 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in Harrow Health in the 4th quarter worth approximately $104,000. BlackRock Inc. raised its holdings in Harrow Health by 3.9% in the 4th quarter. BlackRock Inc. now owns 431,267 shares of the company’s stock worth $3,725,000 after acquiring an additional 16,381 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Harrow Health by 31.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 119,353 shares of the company’s stock worth $1,085,000 after acquiring an additional 28,880 shares during the last quarter. Institutional investors own 43.57% of the company’s stock.

About Harrow Health (Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Featured Articles

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.